Sacituzumab Govitecan-hziy (SG) Clinical Trials

2 actively recruiting trials across 2 locations

▼ -1 trial since June 2026

Also known as: GS-0132, IMMU-132, Trodelvy, Trodelvy™

Pipeline

Phase 3: 1Phase 1/2: 1

Top Sponsors

Gilead Sciences2

Indications

Triple Negative Breast Cancer2
Breast Cancer2
Cancer2

Birmingham, Alabama1 trial

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Alabama Oncology

Phase 3

Los Angeles, California1 trial

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

Los Angeles Cancer Network (LACN) - Good Sam

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.